What question did this study set out to answer?

December 7, 2025ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

View Full Paper

Ask AI

Bookmark

Authors

LFLorenzo FalchiMemorial Sloan Kettering Cancer Center MNMarcel NijlandUniversity Medical Center Groningen HHHuiqiang HuangSun Yat-sen University

Discussion

Member takes

Implication

Randomized trial shows superior progression-free survival with epcoritamab plus lenalidomide and rituximab in relapsed follicular lymphoma, indicating a potential new standard of care.

Key Points

To evaluate the efficacy and safety of adding epcoritamab to lenalidomide and rituximab versus lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma.
Open-label, multicountry phase 3 randomized trial across 189 academic and non-academic centers in 30 countries enrolling 488 participants with relapsed or refractory follicular lymphoma after at least one prior chemoimmunotherapy line (NCT05409066).
Participants were randomly assigned (1:1) to receive fixed-duration epcoritamab plus lenalidomide and rituximab (n=243) or lenalidomide and rituximab alone (n=245) for up to 12 cycles.
Dual primary endpoints evaluated by an independent review committee were overall response rate and progression-free survival over a median follow-up of 14.8 months (IQR 11.4–19.0).
Overall response rate was significantly higher with epcoritamab plus lenalidomide and rituximab compared to lenalidomide and rituximab alone (95% [95% CI 92–97] vs 79% [95% CI 74–84]; p<0.0001).
Progression-free survival was significantly prolonged with the epcoritamab combination (hazard ratio 0.21 [95% CI 0.14–0.31], p<0.0001), with an estimated 16-month progression-free survival rate of 85.5% versus 40.2%.
Grade 3 or higher adverse events occurred in 90% (219/243) of the epcoritamab group versus 68% (161/238) of the control group, while cytokine release syndrome was low grade (grade 1 in 21%, grade 2 in 5%) and completely resolved.

Cite This Study

Falchi et al. (2025) studied this question.

synapsesocial.com/papers/6a995f80cdb6b1cb7af5c3a4 https://doi.org/10.1016/s0140-6736(25)02360-8

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows superior progression-free survival with epcoritamab plus lenalidomide and rituximab in relapsed follicular lymphoma, indicating a potential new standard of care.

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider